Castle Biosciences
Yahoo Finance • 12 months ago
Real-World Evidence Confirms IDgenetix®-Guided Medication Management Significantly Improves Response and Remission Rates in Patients with Major Depressive Disorder
IDgenetix is a clinically validated pharmacogenomic (PGx) test that incorporates drug-gene interactions, drug-drug interactions and lifestyle factors to guide medication management for patients’ neuropsychiatric conditions, such as depress... Full story
Yahoo Finance • last year
Bragar Eagel & Squire, P.C. Is Investigating Advance Auto Parts, EPAM, and Castle and Encourages Investors to Contact the Firm
NEW YORK, July 10, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Advance Auto Parts, Inc. (NYSE: AAP), EPAM Systems, Inc. (NYSE: EPAM)... Full story
Yahoo Finance • last year
Bragar Eagel & Squire, P.C. Is Investigating Advance Auto Parts, EPAM, and Castle Biosciences and Encourages Investors to Contact the Firm
NEW YORK, July 05, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Advance Auto Parts, Inc. (NYSE: AAP), EPAM Systems, Inc. (NYSE: EPAM)... Full story
Yahoo Finance • last year
Bragar Eagel & Squire, P.C. Is Investigating EPAM, Castle, BeiGene and Fox and Encourages Investors to Contact the Firm
NEW YORK, June 30, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against EPAM Systems, Inc. (NYSE: EPAM), Castle Biosciences, Inc. (NASDAQ: CS... Full story
Yahoo Finance • last year
Bragar Eagel & Squire, P.C. Is Investigating Comerica, Advance Auto Parts, EPAM, and Castle and Encourages Investors to Contact the Firm
NEW YORK, June 25, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Comerica Incorporated (NYSE: CMA), Advance Auto Parts, Inc. (NYSE: AA... Full story
Yahoo Finance • last year
Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
FRIENDSWOOD, Texas, June 20, 2023--(BUSINESS WIRE)--Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that on June 16, 2023, the Compensation Committee of... Full story
Yahoo Finance • last year
Bragar Eagel & Squire, P.C. Is Investigating Texas Capital, EPAM, and Castle and Encourages Investors to Contact the Firm
NEW YORK, June 19, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Texas Capital Bancshares, Inc. (NASDAQ: TCBI), EPAM Systems, Inc. (NY... Full story
Yahoo Finance • last year
Kirby McInerney LLP Continues Investigation of Shareholder Claims Against Castle BioSciences, Inc. (CSTL)
NEW YORK, June 13, 2023 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential claims against Castle Biosciences, Inc. (“Castle” or the “Company”) (NASDAQ: CSTL). The investigation concerns whether Castle and/... Full story
Yahoo Finance • 2 years ago
DecisionDx®-Melanoma Provides Improved Risk Stratification Over American Joint Committee on Cancer (AJCC) Staging Alone in Stage I Melanoma Patients
New data shared in a poster presentation during the 19th European Association of Dermato-Oncology (EADO) Congress FRIENDSWOOD, Texas, April 25, 2023--(BUSINESS WIRE)--Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health thr... Full story
Yahoo Finance • 2 years ago
Castle Biosciences to Host Investor Day on Sept. 20, 2022
FRIENDSWOOD, Texas, August 24, 2022--(BUSINESS WIRE)--Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, will host an Investor Day on Sept. 20, 2022. Derek Maetzold, presi... Full story
Yahoo Finance • 2 years ago
Castle Biosciences Reports Second Quarter 2022 Results
Q2 2022 revenue increased 53% over Q2 2021 to $34.8 million Delivered 11,034 total test reports in Q2 2022, an increase of 57% compared to Q2 2021 Skin cancer gene expression profile test report volume increased 44% compared to Q2 2021 Rai... Full story
Yahoo Finance • 3 years ago
Data to be Presented at the 2022 American Academy of Dermatology (AAD) Annual Meeting Demonstrate Ability of DecisionDx®-Melanoma and DecisionDx®-SCC to Inform Clinical Decision Making
FRIENDSWOOD, Texas, March 25, 2022--(BUSINESS WIRE)--Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced upcoming presentations on two of its skin cancer gen... Full story
